Frequently Asked Questions
The market is segmented based on , By Age Group (Child and Adult), Type (Asperger Syndrome, Pervasive Developmental Disorder, and Autistic Disorder), Treatment Type (ABA, Hyperbaric Oxygen Therapy, Chelation Therapy, Oxytocin Therapy, Communication and Behavioural Therapy, and Others), Drug (Anticonvulsants, Antipsychotics, Insomnia Drugs, SSRIs, Stimulants, and Others), Distribution Channel (Hospital and Clinics, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2031.
.
The Global Autism Therapy Market size was valued at USD 2.19 USD Billion in 2023.
The Global Autism Therapy Market is projected to grow at a CAGR of 6.6% during the forecast period of 2024 to 2031.
The major players operating in the market include Pfizer Inc. (U.S.), The Lily Center (U.S.), Abbvie, Inc (U.S.), Merck & Co., Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Hopebridge, LLC. (U.S.), Bristol-Myers Squibb Company (U.S.), Otsuka America Pharmaceutical, Inc (Japan), Curemark, LLC (U.S.)., Sun Pharmaceutical Industries Ltd. (India), Mylan N.V. (U.S.), Endo, Inc. (Ireland), F. Hoffmann-La Roche Ltd (Switzerland).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
